Clinical Trials
116 trialsPerioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone
Emory University
EXCEED
Eli Lilly and Company
NEXUS-01
Eli Lilly and Company
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
M.D. Anderson Cancer Center
FORAGER-1
Eli Lilly and Company
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
EV-309
Astellas Pharma Inc
LIAM Mc
University College Cork
FC-VE
University Hospital, Linkoeping
CHEMOVES
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
IMMUNO-SUP
Institut Paoli-Calmettes
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
M.D. Anderson Cancer Center
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
EV-103
Astellas Pharma Inc
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
BOOST
Relmada Therapeutics, Inc.
RESCUE
Relmada Therapeutics, Inc.
RESCUE
Relmada Therapeutics, Inc.
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Memorial Sloan Kettering Cancer Center
PORTICO
Luzerner Kantonsspital
Web-Based Application for Monitoring Radiation Therapy Complications in Cancer Patients
Institute of Oncology Ljubljana
SURF301
Tyra Biosciences, Inc
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
CG Oncology, Inc.
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
M.D. Anderson Cancer Center
CD70-targeted immunoPET Imaging of Kidney Cancer
RenJi Hospital
Comparison of the Integrated Posterior-Anterior-Lateral Approach and the Posterior Approach in Robotic Radical Prostatectomy
The First Affiliated Hospital of Zhengzhou University
UROVISIO
Lille Catholic University
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen Inc.
PRIAM
The Netherlands Cancer Institute
UUTICaD
University Hospital, Toulouse
MOST-D
Heinrich-Heine University, Duesseldorf
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
PAVO
Tempus AI
RAD-VACCINE
The Methodist Hospital Research Institute
Vaginal Dilator Therapy After Pelvic Radiation
Duke University
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
TURANDORELA
The Netherlands Cancer Institute
FMBRT
Cedars-Sinai Medical Center
PREVENT-GU
Ottawa Hospital Research Institute
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology LLC
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
PALLSOFT
Sykehuset Telemark
Meteor 1
GlaxoSmithKline
Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
EV-201
Astellas Pharma Inc
A Study of Cadonilimab(AK104)Combined With Standard Treatment for Function Preservation in Urinary System Tumors
Tongji Hospital
PAPRAC
Insel Gruppe AG, University Hospital Bern
MV
Royal Marsden NHS Foundation Trust
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
Hoffmann-La Roche
JAVELIN Bladder 100
Pfizer